Wall Street analysts forecast that NxStage Medical, Inc. (NASDAQ:NXTM) will announce $105.35 million in sales for the current quarter, according to Zacks. Three analysts have issued estimates for NxStage Medical’s earnings, with the lowest sales estimate coming in at $103.40 million and the highest estimate coming in at $107.85 million. NxStage Medical reported sales of $96.22 million during the same quarter last year, which would suggest a positive year over year growth rate of 9.5%. The company is scheduled to announce its next quarterly earnings results on Monday, September 17th.

According to Zacks, analysts expect that NxStage Medical will report full-year sales of $430.57 million for the current financial year, with estimates ranging from $426.10 million to $435.91 million. For the next fiscal year, analysts anticipate that the company will post sales of $467.80 million per share, with estimates ranging from $467.30 million to $468.30 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover NxStage Medical.

Several research analysts recently commented on the company. BidaskClub upgraded NxStage Medical from a “sell” rating to a “hold” rating in a research report on Tuesday. Zacks Investment Research lowered NxStage Medical from a “hold” rating to a “sell” rating in a research report on Saturday, August 11th. Finally, ValuEngine lowered NxStage Medical from a “buy” rating to a “hold” rating in a research report on Tuesday, August 7th. One equities research analyst has rated the stock with a sell rating and four have issued a hold rating to the company’s stock. NxStage Medical presently has an average rating of “Hold” and a consensus target price of $30.00.

Large investors have recently made changes to their positions in the business. NumerixS Investment Technologies Inc purchased a new position in shares of NxStage Medical during the second quarter valued at approximately $122,000. Steward Partners Investment Advisory LLC boosted its position in shares of NxStage Medical by 714.3% during the second quarter. Steward Partners Investment Advisory LLC now owns 5,700 shares of the medical device company’s stock valued at $159,000 after buying an additional 5,000 shares during the period. Keybank National Association OH purchased a new position in shares of NxStage Medical during the second quarter valued at approximately $212,000. Quantitative Systematic Strategies LLC purchased a new position in shares of NxStage Medical during the second quarter valued at approximately $216,000. Finally, Janus Henderson Group PLC purchased a new position in shares of NxStage Medical during the second quarter valued at approximately $234,000. Institutional investors and hedge funds own 83.23% of the company’s stock.

NXTM traded down $0.04 on Friday, hitting $28.28. The company had a trading volume of 547,300 shares, compared to its average volume of 475,140. The firm has a market cap of $1.86 billion, a P/E ratio of -128.89 and a beta of -0.05. NxStage Medical has a 12-month low of $22.70 and a 12-month high of $28.75.

About NxStage Medical

NxStage Medical, Inc, a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting.

Further Reading: Understanding Average Daily Trade Volume

Get a free copy of the Zacks research report on NxStage Medical (NXTM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.